University of Texas System Oral Delivery Formulation Patent Application, Apr 23, 2026
Summary
The Board of Regents of the University of Texas System has filed USPTO Patent Application US20260108502A1 for oral delivery formulations using self-emulsifying granules and lipid-based granules prepared via additive manufacturing (sintering or melting processes). The compositions form self-emulsifying drug delivery systems and lipid-coated drug particles. This represents a new pharmaceutical composition patent filing; no immediate compliance obligations are imposed.
“The present disclosure provides compositions and methods of preparing compositions comprising using lipid containing pharmaceutical compositions that are prepared using an additive manufacturing technique such as a sintering or melting process.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
The USPTO has published Patent Application US20260108502A1 filed by the University of Texas System, covering pharmaceutical compositions prepared using additive manufacturing techniques (sintering or melting) to create self-emulsifying drug delivery systems and lipid-coated drug particles. The compositions utilize lipid-containing pharmaceutical formulations. CPC classifications include A61K 31/427, A61K 9/1617, A61K 9/1641, A61K 9/1694, and A61P 35/00.
Pharmaceutical manufacturers and drug developers with interests in oral drug delivery, lipid-based formulations, or 3D-printed pharmaceuticals may wish to monitor the prosecution of this application for potential freedom-to-operate considerations or licensing opportunities. The application represents a novel intersection of additive manufacturing and pharmaceutical science with potential applications in cancer therapeutics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ORAL DELIVERY FORMULATIONS USING SELF EMULSIFYING GRANULES AND LIPID BASED GRANULES
Application US20260108502A1 Kind: A1 Apr 23, 2026
Assignee
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors
Mohammed MANIRUZZAMAN, Bhupendra RAJ GIRI, Vineet R. KULKARNI
Abstract
The present disclosure provides compositions and methods of preparing compositions comprising using lipid containing pharmaceutical compositions that are prepared using an additive manufacturing technique such as a sintering or melting process. The pharmaceutical compositions may form self emulsifying drug delivery systems. The pharmaceutical compositions may form lipid coated drug particles that are formed from the melting of the lipid through the additive manufacturing process.
CPC Classifications
A61K 31/427 A61K 9/1617 A61K 9/1641 A61K 9/1694 A61P 35/00
Filing Date
2025-10-21
Application No.
19364498
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.